PEPG Company Profile and Key Details

PEPG has shown sold momentum, gaining 4.75% over the past week and 21.68% over the past quarter, though year-to-date performance is down -8.6%. Short-term trend indicators are bearishly aligned (SMA20 -1.2%, SMA50 5.7%, SMA200 100.41%). The stock’s 14-day RSI is 51.51 (neutral), while the ATR of 0.57 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -23.72% below its high and over 576.06% above its low. Average 10-day trading volume of 875.59 thousand shares is slightly above the 3-month average of 735.82 thousand, indicating heightened recent market interest.

PepGen Inc. has 32.80 million shares outstanding. The public float is 14.53 million shares, elevated short interest at 6.54% of float. This equals 1.13 million shares. The short ratio is 3.54 days. Institutional investors hold 89.74% of the float. Insiders own 0.27%. RA CAPITAL MANAGEMENT, L.P. holds 18.55 million shares, Oxford Science Enterprises plc has 4.96 million shares and Shah Rajeev M. has 1.30 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

PepGen Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.97. This means the shares are trading above this model’s fair value.

PepGen Inc. generated EPS of -$2.84 over the past year. Five-year average earnings growth is -116.35%. Wall Street analysts project EPS growth of 27.19% annually over the next five years. The latest quarter delivered EPS of -$0.55. The next quarter is forecast at -$0.35. Next year's EPS is expected at -$4.57. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $26.00 to $6.00. The high target offers 336.97% upside. The low target suggests 0.84% downside. The mean target is $13.30. This offers 123.53% upside. PepGen Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -12.63%. The prior quarter beat by -17.65%. Over the last six quarters, Apple has recorded several small beats. These include 20.83% in August 08, 2024.

PepGen Inc. (NASDAQ:PEPG) closed at $5.40 USD, losing -$0.55 (-9.24%) from the previous close of $5.95. The stock is currently mid-range between its 52-week high and low $0.88 and $7.80. With a market capitalization of about $371.24 million, PepGen Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.92). Key stats such as the average daily volume over the past year has been around 740.85 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, PepGen Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO James G. McArthur, the company employs approximately 79 people and listed since May 06, 2022. PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.

PepGen Inc. (NASDAQ:PEPG) shares are flat -8.6% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows PepGen Inc. trading at a premium to the broader market with a P/E of -2.11. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $18.20, suggesting 205.88% upside. Our AI forecast model points to short-term strength (2.52% over two weeks), a medium-term fall (-34.62% over three months), and a longer-term gain (538.49% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that PepGen Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.52%, with price expected at $6.10 by February 03, 2026, within a range of $5.39 to $6.81 3-Month Outlook: Projected fall of -34.62%, reaching $3.89 by April 16, 2026, with a range of $3.43 to $4.19. 1-Year Outlook: Projected gain of 538.49%, with price at $37.99 by January 15, 2027, within a range of $40.04 to $43.57.

PepGen Inc. trades at a P/E ratio of -2.11, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.21 suggesting the stock is closer to book value. The P/FCF stands at -4.83, also below market averages.